Published: 16 June 2023
Author(s): Mai Kawazoe, Junko Nishio, Wataru Hirose, Karin Furukawa, Toshihiro Nanki

Patients with rheumatic diseases (RD) have a higher rate of poor outcomes of coronavirus disease 2019 (COVID-19) [1]. The American College of Rheumatology (ACR) and the European League Against Rheumatism strongly recommended RD patients to receive the vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2,3]. Unvaccinated patients are at an increased risk of not only infection, but also hospitalization and death [1]. However, efficacy and safety data on vaccines for RD patients were initially unavailable because phase III clinical trials on these vaccines excluded patients receiving immunosuppressive agents.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.